Search Results - "Selzler, Katherine J"

Trial of Solanezumab for Mild Dementia Due to Alzheimer’s Disease by Honig, Lawrence S, Vellas, Bruno, Woodward, Michael, Boada, Mercè, Bullock, Roger, Borrie, Michael, Hager, Klaus, Andreasen, Niels, Scarpini, Elio, Liu-Seifert, Hong, Case, Michael, Dean, Robert A, Hake, Ann, Sundell, Karen, Poole Hoffmann, Vicki, Carlson, Christopher, Khanna, Rashna, Mintun, Mark, DeMattos, Ronald, Selzler, Katherine J, Siemers, Eric

“…In a randomized trial, solanezumab, a humanized monoclonal antibody against soluble amyloid, did not slow cognitive decline over a period of 80 weeks in…”
Get full text

A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraine by Camporeale, Angelo, Kudrow, David, Sides, Ryan, Wang, Shufang, Van Dycke, Annelies, Selzler, Katherine J, Stauffer, Virginia L

“…Galcanezumab, a humanized monoclonal antibody that selectively binds to the calcitonin gene-related peptide, has demonstrated in previous Phase 2 and Phase 3…”
Get full text

Comprehensive population-based survey of migraine in Japan: results of the ObserVational Survey of the Epidemiology, tReatment, and Care Of MigrainE (OVERCOME [Japan]) study by Hirata, Koichi, Ueda, Kaname, Komori, Mika, Zagar, Anthony J., Selzler, Katherine J., Nelson, Ann Marie, Han, Yimei, Jaffe, Dena H., Matsumori, Yasuhiko, Takeshima, Takao

“…The ObserVational survey of the Epidemiology, tReatment, and Care Of MigrainE study in Japan (OVERCOME [Japan]) aimed to provide an up-to-date assessment of…”
Get full text

Galcanezumab in chronic migraine: The randomized, double-blind, placebo-controlled REGAIN study by Detke, Holland C, Goadsby, Peter J, Wang, Shufang, Friedman, Deborah I, Selzler, Katherine J, Aurora, Sheena K

“…OBJECTIVETo evaluate the efficacy and safety of galcanezumab, a humanized monoclonal antibody that selectively binds to calcitonin gene-related peptide, in the…”
Get full text

Lanabecestat: Neuroimaging results in early symptomatic Alzheimer's disease by Zimmer, Jennifer A., Shcherbinin, Sergey, Devous, Michael D., Bragg, Sonja M., Selzler, Katherine J., Wessels, Alette M., Shering, Craig, Mullen, Jamie, Landry, John, Andersen, Scott W., Downing, AnnCatherine M., Fleisher, Adam S., Svaldi, Diana Otero, Sims, John R.

“…Introduction Lanabecestat, a beta‐site amyloid precursor protein‐cleaving enzyme 1 (BACE1) inhibitor, was investigated as a potential Alzheimer's disease…”
Get full text

Efficacy and Safety of Lanabecestat for Treatment of Early and Mild Alzheimer Disease: The AMARANTH and DAYBREAK-ALZ Randomized Clinical Trials by Wessels, Alette M, Tariot, Pierre N, Zimmer, Jennifer A, Selzler, Katherine J, Bragg, Sonja M, Andersen, Scott W, Landry, John, Krull, James H, Downing, AnnCatherine M, Willis, Brian A, Shcherbinin, Sergey, Mullen, Jamie, Barker, Peter, Schumi, Jennifer, Shering, Craig, Matthews, Brandy R, Stern, Robert A, Vellas, Bruno, Cohen, Sharon, MacSweeney, Emer, Boada, Mercè, Sims, John R

“…Alzheimer disease (AD) is a neurodegenerative disorder characterized by cognitive deterioration and impaired activities of daily living. Current treatments…”
Get more information

An overview of the pathophysiology of agitation in Alzheimer's dementia with a focus on neurotransmitters and circuits by Cummings, Jeffrey L, Brubaker, Malaak, Selzler, Katherine J, Gonzalez, Sarah T, Patel, Mehul, Stahl, Stephen M

“…Alzheimer's dementia (AD) is a progressive, neurodegenerative disease often accompanied by neuropsychiatric symptoms that profoundly impact both patients and…”
Get full text

Longitudinal study to assess antidepressant treatment patterns and outcomes in individuals with depression in the general population by Ohayon, Maurice M., McCue, Maggie, Krystal, Andrew, Selzler, Katherine J., Chrones, Lambros, Lawrence, Debra, Côté, Marie-Lise

“…Major depressive disorder (MDD) is largely managed in primary care, but physicians vary widely in their understanding of symptoms and treatments. This study…”
Get full text

Cognitive Impairment Precedes and Predicts Functional Impairment in Mild Alzheimer's Disease by Liu-Seifert, Hong, Siemers, Eric, Price, Karen, Han, Baoguang, Selzler, Katherine J, Henley, David, Sundell, Karen, Aisen, Paul, Cummings, Jeffrey, Raskin, Joel, Mohs, Richard

“…The temporal relationship of cognitive deficit and functional impairment in Alzheimer's disease (AD) is not well characterized. Recent analyses suggest…”
Get more information

Comparison between prefilled syringe and autoinjector devices on patient-reported experiences and pharmacokinetics in galcanezumab studies by Stauffer, Virginia L, Sides, Ryan, Lanteri-Minet, Michel, Kielbasa, William, Jin, Yan, Selzler, Katherine J, Tepper, Stewart J

“…The aim of this study was to compare the usability and patient-rated experiences of an autoinjector with a prefilled syringe in patients with migraine, who…”
Get full text

DOES HIPPOCAMPAL VOLUME PREDICT POSITIVE AMYLOID STATUS ON FLORBETAPIR-PET IN HEALTHY CONTROLS AND PRODROMAL STAGES OF ALZHEIMER'S DISEASE? by Trzepacz, Paula T, Peng, Yu, Castelluccio, Peter, Hochstetler, Helen M, Joshi, Abhinay, Dell'Agnello, Grazia, Degenhardt, Elisabeth K, Selzler, Katherine J, Witte, Michael M, Devous, Michael D, Schwarz, Adam J

Get full text

Detection of Early Alzheimer’s disease at AdventHealth: A Davos Alzheimer’s Collaborative flagship site by Baldivieso, Valeria, Erickson, Kirk I., Smith, Steven R., Pratley, Richard E., Baksh, Magda R., Shepherd, Gayle, Lopez, Janice, Jain, Shivangi, Selzler, Katherine J., Murray, James F, West, Tim, Ortega, Julia, Coppinger, Justine, Venkatesh, Venky, Monane, Mark, Braunstein, Joel B.

“…Background Early identification of Alzheimer’s disease (AD) is critical for disease‐modifying therapies. The Davos Alzheimer’s Collaborative flagship program…”
Get full text

PERFORMANCE ON EXPLORATORY EFFICACY VARIABLES IN AMARANTH, A RANDOMIZED PHASE 2/3 STUDY IN EARLY ALZHEIMER’S DISEASE WITH LANABECESTAT by Stern, Robert A., Wessels, Alette M., Selzler, Katherine J., Andersen, Scott W., Mullen, Jamie, Sims, John R.

Get full text

SUBGROUP POPULATIONS IN AMARANTH, A RANDOMIZED PHASE 2/3 STUDY IN EARLY ALZHEIMER’S DISEASE WITH LANABECESTAT by Tariot, Pierre N., Selzler, Katherine J., Wessels, Alette M., Andersen, Scott W., Mullen, Jamie, Zimmer, Jennifer A., Sims, John R.

Get full text

FTS3‐01‐02: SUBGROUP POPULATIONS IN AMARANTH, A RANDOMIZED PHASE 2/3 STUDY IN EARLY ALZHEIMER'S DISEASE WITH LANABECESTAT by Tariot, Pierre N., Selzler, Katherine J., Wessels, Alette M., Andersen, Scott W., Mullen, Jamie, Zimmer, Jennifer A., Sims, John R.

Get full text

FTS3‐01‐03: PERFORMANCE ON EXPLORATORY EFFICACY VARIABLES IN AMARANTH, A RANDOMIZED PHASE 2/3 STUDY IN EARLY ALZHEIMER'S DISEASE WITH LANABECESTAT by Stern, Robert A., Wessels, Alette M., Selzler, Katherine J., Andersen, Scott W., Mullen, Jamie, Sims, John R.

Get full text

FTS3‐01‐02: SUBGROUP POPULATIONS IN AMARANTH, A RANDOMIZED PHASE 2/3 STUDY IN EARLY ALZHEIMER'S DISEASE WITH LANABECESTAT by Tariot, Pierre N., Selzler, Katherine J., Wessels, Alette M., Andersen, Scott W., Mullen, Jamie, Zimmer, Jennifer A., Sims, John R.

Get full text

P4‐136: DOES HIPPOCAMPAL VOLUME PREDICT POSITIVE AMYLOID STATUS ON FLORBETAPIR‐PET IN HEALTHY CONTROLS AND PRODROMAL STAGES OF ALZHEIMER'S DISEASE? by Trzepacz, Paula T., Peng, Yu, Castelluccio, Peter, Hochstetler, Helen M., Joshi, Abhinay, Dell'Agnello, Grazia, Degenhardt, Elisabeth K., Selzler, Katherine J., Witte, Michael M., Devous, Michael D., Schwarz, Adam J.

Get full text